Farletuzumab - Morphotek

Drug Profile

Farletuzumab - Morphotek

Alternative Names: Anti-GP-3 humanised mAb; Anti-GP3 humanised monoclonal antibody; MORAb-003

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ludwig Institute for Cancer Research; Morphotek
  • Developer Eisai Co Ltd; Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Oct 2016 Farletuzumab licensed to Eurofarma in Latin America
  • 18 Apr 2016 Interim safety and efficacy results from phase III FAR 131 trial and sub-group anaylsis study were reported by the Morphotek
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top